Toolkit/in vivo PET ([(11)C]-PE2I)

in vivo PET ([(11)C]-PE2I)

Assay Method·Research·Since 2014

Taxonomy: Technique Branch / Method. Workflows sit above the mechanism and technique branches rather than replacing them.

Summary

In vivo PET with [(11)C]-PE2I is a radiotracer imaging assay used to assess dopamine degeneration in MPTP-treated non-human primates. In the cited study, it was applied alongside post-mortem tyrosine hydroxylase and dopamine transporter quantification.

Usefulness & Problems

Why this is useful

This assay provides an in vivo readout for dopamine degeneration in a non-human primate MPTP model. Its utility in the supplied evidence is as part of a multimodal assessment combined with post-mortem TH and DAT measurements.

Problem solved

It addresses the need to assess dopaminergic degeneration in living MPTP-treated non-human primates. The evidence does not provide further detail on assay performance metrics or analytical outputs.

Taxonomy & Function

Primary hierarchy

Technique Branch

Method: A concrete measurement method used to characterize an engineered system.

Target processes

No target processes tagged yet.

Implementation Constraints

cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationoperating role: sensor

Implementation requires positron emission tomography using the radiotracer [(11)C]-PE2I in non-human primates. The cited study also incorporated post-mortem TH and DAT quantification, but the supplied evidence does not specify acquisition parameters, dosing, or analysis methods.

The evidence is limited to a single stated use case in MPTP-treated non-human primates. No details are provided on tracer kinetics, imaging protocol, quantification strategy, or validation beyond association with post-mortem TH and DAT measurements.

Validation

Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication

Supporting Sources

Ranked Claims

Claim 1assay usagesupports2014Source 1needs review

Dopamine degeneration in the MPTP non-human primate model was assessed using in vivo PET with [(11)C]-PE2I and post-mortem TH and DAT quantification.

DA degeneration was assessed by in vivo PET ([(11)C]-PE2I) and post-mortem TH and DAT quantification.
Claim 2assay usagesupports2014Source 1needs review

Dopamine degeneration in the MPTP non-human primate model was assessed using in vivo PET with [(11)C]-PE2I and post-mortem TH and DAT quantification.

DA degeneration was assessed by in vivo PET ([(11)C]-PE2I) and post-mortem TH and DAT quantification.
Claim 3assay usagesupports2014Source 1needs review

Dopamine degeneration in the MPTP non-human primate model was assessed using in vivo PET with [(11)C]-PE2I and post-mortem TH and DAT quantification.

DA degeneration was assessed by in vivo PET ([(11)C]-PE2I) and post-mortem TH and DAT quantification.
Claim 4assay usagesupports2014Source 1needs review

Dopamine degeneration in the MPTP non-human primate model was assessed using in vivo PET with [(11)C]-PE2I and post-mortem TH and DAT quantification.

DA degeneration was assessed by in vivo PET ([(11)C]-PE2I) and post-mortem TH and DAT quantification.
Claim 5assay usagesupports2014Source 1needs review

Dopamine degeneration in the MPTP non-human primate model was assessed using in vivo PET with [(11)C]-PE2I and post-mortem TH and DAT quantification.

DA degeneration was assessed by in vivo PET ([(11)C]-PE2I) and post-mortem TH and DAT quantification.
Claim 6assay usagesupports2014Source 1needs review

Dopamine degeneration in the MPTP non-human primate model was assessed using in vivo PET with [(11)C]-PE2I and post-mortem TH and DAT quantification.

DA degeneration was assessed by in vivo PET ([(11)C]-PE2I) and post-mortem TH and DAT quantification.
Claim 7assay usagesupports2014Source 1needs review

Dopamine degeneration in the MPTP non-human primate model was assessed using in vivo PET with [(11)C]-PE2I and post-mortem TH and DAT quantification.

DA degeneration was assessed by in vivo PET ([(11)C]-PE2I) and post-mortem TH and DAT quantification.
Claim 8circadian challenge responsesupports2014Source 1needs review

Under constant light, dopamine-depleted non-human primates have severely disturbed or abolished locomotor rhythms, while controls retain free-running locomotor rest-wake and hormonal rhythms with stable phase relationships.

When the circadian system is challenged by exposure to constant light, controls retain locomotor rest-wake and hormonal rhythms that free-run with stable phase relationships whereas in the DA-depleted NHP, locomotor rhythms are severely disturbed or completely abolished.
Claim 9circadian challenge responsesupports2014Source 1needs review

Under constant light, dopamine-depleted non-human primates have severely disturbed or abolished locomotor rhythms, while controls retain free-running locomotor rest-wake and hormonal rhythms with stable phase relationships.

When the circadian system is challenged by exposure to constant light, controls retain locomotor rest-wake and hormonal rhythms that free-run with stable phase relationships whereas in the DA-depleted NHP, locomotor rhythms are severely disturbed or completely abolished.
Claim 10circadian challenge responsesupports2014Source 1needs review

Under constant light, dopamine-depleted non-human primates have severely disturbed or abolished locomotor rhythms, while controls retain free-running locomotor rest-wake and hormonal rhythms with stable phase relationships.

When the circadian system is challenged by exposure to constant light, controls retain locomotor rest-wake and hormonal rhythms that free-run with stable phase relationships whereas in the DA-depleted NHP, locomotor rhythms are severely disturbed or completely abolished.
Claim 11circadian challenge responsesupports2014Source 1needs review

Under constant light, dopamine-depleted non-human primates have severely disturbed or abolished locomotor rhythms, while controls retain free-running locomotor rest-wake and hormonal rhythms with stable phase relationships.

When the circadian system is challenged by exposure to constant light, controls retain locomotor rest-wake and hormonal rhythms that free-run with stable phase relationships whereas in the DA-depleted NHP, locomotor rhythms are severely disturbed or completely abolished.
Claim 12circadian challenge responsesupports2014Source 1needs review

Under constant light, dopamine-depleted non-human primates have severely disturbed or abolished locomotor rhythms, while controls retain free-running locomotor rest-wake and hormonal rhythms with stable phase relationships.

When the circadian system is challenged by exposure to constant light, controls retain locomotor rest-wake and hormonal rhythms that free-run with stable phase relationships whereas in the DA-depleted NHP, locomotor rhythms are severely disturbed or completely abolished.
Claim 13circadian challenge responsesupports2014Source 1needs review

Under constant light, dopamine-depleted non-human primates have severely disturbed or abolished locomotor rhythms, while controls retain free-running locomotor rest-wake and hormonal rhythms with stable phase relationships.

When the circadian system is challenged by exposure to constant light, controls retain locomotor rest-wake and hormonal rhythms that free-run with stable phase relationships whereas in the DA-depleted NHP, locomotor rhythms are severely disturbed or completely abolished.
Claim 14circadian challenge responsesupports2014Source 1needs review

Under constant light, dopamine-depleted non-human primates have severely disturbed or abolished locomotor rhythms, while controls retain free-running locomotor rest-wake and hormonal rhythms with stable phase relationships.

When the circadian system is challenged by exposure to constant light, controls retain locomotor rest-wake and hormonal rhythms that free-run with stable phase relationships whereas in the DA-depleted NHP, locomotor rhythms are severely disturbed or completely abolished.
Claim 15hormonal rhythm observationsupports2014Source 1needs review

Hormonal rhythm amplitude and phase relations remain unaltered in dopamine-depleted non-human primates despite locomotor rhythm disruption under constant light.

The amplitude and phase relations of hormonal rhythms nevertheless remain unaltered.
Claim 16hormonal rhythm observationsupports2014Source 1needs review

Hormonal rhythm amplitude and phase relations remain unaltered in dopamine-depleted non-human primates despite locomotor rhythm disruption under constant light.

The amplitude and phase relations of hormonal rhythms nevertheless remain unaltered.
Claim 17hormonal rhythm observationsupports2014Source 1needs review

Hormonal rhythm amplitude and phase relations remain unaltered in dopamine-depleted non-human primates despite locomotor rhythm disruption under constant light.

The amplitude and phase relations of hormonal rhythms nevertheless remain unaltered.
Claim 18hormonal rhythm observationsupports2014Source 1needs review

Hormonal rhythm amplitude and phase relations remain unaltered in dopamine-depleted non-human primates despite locomotor rhythm disruption under constant light.

The amplitude and phase relations of hormonal rhythms nevertheless remain unaltered.
Claim 19hormonal rhythm observationsupports2014Source 1needs review

Hormonal rhythm amplitude and phase relations remain unaltered in dopamine-depleted non-human primates despite locomotor rhythm disruption under constant light.

The amplitude and phase relations of hormonal rhythms nevertheless remain unaltered.
Claim 20hormonal rhythm observationsupports2014Source 1needs review

Hormonal rhythm amplitude and phase relations remain unaltered in dopamine-depleted non-human primates despite locomotor rhythm disruption under constant light.

The amplitude and phase relations of hormonal rhythms nevertheless remain unaltered.
Claim 21hormonal rhythm observationsupports2014Source 1needs review

Hormonal rhythm amplitude and phase relations remain unaltered in dopamine-depleted non-human primates despite locomotor rhythm disruption under constant light.

The amplitude and phase relations of hormonal rhythms nevertheless remain unaltered.
Claim 22mechanistic interpretationsupports2014Source 1needs review

Following dopamine lesion, the central clock in the SCN may remain intact, but without environmental timing cues it may be unable to drive downstream striatal clock gene and dopaminergic processes controlling locomotor output.

These results suggest that following DA lesion, the central clock in the SCN remains intact but, in the absence of environmental timing cues, is unable to drive downstream rhythmic processes of striatal clock gene and dopaminergic functions that control locomotor output.
Claim 23mechanistic interpretationsupports2014Source 1needs review

Following dopamine lesion, the central clock in the SCN may remain intact, but without environmental timing cues it may be unable to drive downstream striatal clock gene and dopaminergic processes controlling locomotor output.

These results suggest that following DA lesion, the central clock in the SCN remains intact but, in the absence of environmental timing cues, is unable to drive downstream rhythmic processes of striatal clock gene and dopaminergic functions that control locomotor output.
Claim 24mechanistic interpretationsupports2014Source 1needs review

Following dopamine lesion, the central clock in the SCN may remain intact, but without environmental timing cues it may be unable to drive downstream striatal clock gene and dopaminergic processes controlling locomotor output.

These results suggest that following DA lesion, the central clock in the SCN remains intact but, in the absence of environmental timing cues, is unable to drive downstream rhythmic processes of striatal clock gene and dopaminergic functions that control locomotor output.
Claim 25mechanistic interpretationsupports2014Source 1needs review

Following dopamine lesion, the central clock in the SCN may remain intact, but without environmental timing cues it may be unable to drive downstream striatal clock gene and dopaminergic processes controlling locomotor output.

These results suggest that following DA lesion, the central clock in the SCN remains intact but, in the absence of environmental timing cues, is unable to drive downstream rhythmic processes of striatal clock gene and dopaminergic functions that control locomotor output.
Claim 26mechanistic interpretationsupports2014Source 1needs review

Following dopamine lesion, the central clock in the SCN may remain intact, but without environmental timing cues it may be unable to drive downstream striatal clock gene and dopaminergic processes controlling locomotor output.

These results suggest that following DA lesion, the central clock in the SCN remains intact but, in the absence of environmental timing cues, is unable to drive downstream rhythmic processes of striatal clock gene and dopaminergic functions that control locomotor output.
Claim 27mechanistic interpretationsupports2014Source 1needs review

Following dopamine lesion, the central clock in the SCN may remain intact, but without environmental timing cues it may be unable to drive downstream striatal clock gene and dopaminergic processes controlling locomotor output.

These results suggest that following DA lesion, the central clock in the SCN remains intact but, in the absence of environmental timing cues, is unable to drive downstream rhythmic processes of striatal clock gene and dopaminergic functions that control locomotor output.
Claim 28mechanistic interpretationsupports2014Source 1needs review

Following dopamine lesion, the central clock in the SCN may remain intact, but without environmental timing cues it may be unable to drive downstream striatal clock gene and dopaminergic processes controlling locomotor output.

These results suggest that following DA lesion, the central clock in the SCN remains intact but, in the absence of environmental timing cues, is unable to drive downstream rhythmic processes of striatal clock gene and dopaminergic functions that control locomotor output.
Claim 29phenotype differencesupports2014Source 1needs review

In a light-dark cycle, MPTP-treated dopamine-depleted non-human primates retain rest-wake locomotor rhythms but show reduced amplitude, decreased stability, and increased fragmentation relative to controls.

In a light∶dark cycle, control and MPTP-treated NHP both exhibit rest-wake locomotor rhythms, although DA-depleted NHP show reduced amplitude, decreased stability and increased fragmentation.
Claim 30phenotype differencesupports2014Source 1needs review

In a light-dark cycle, MPTP-treated dopamine-depleted non-human primates retain rest-wake locomotor rhythms but show reduced amplitude, decreased stability, and increased fragmentation relative to controls.

In a light∶dark cycle, control and MPTP-treated NHP both exhibit rest-wake locomotor rhythms, although DA-depleted NHP show reduced amplitude, decreased stability and increased fragmentation.
Claim 31phenotype differencesupports2014Source 1needs review

In a light-dark cycle, MPTP-treated dopamine-depleted non-human primates retain rest-wake locomotor rhythms but show reduced amplitude, decreased stability, and increased fragmentation relative to controls.

In a light∶dark cycle, control and MPTP-treated NHP both exhibit rest-wake locomotor rhythms, although DA-depleted NHP show reduced amplitude, decreased stability and increased fragmentation.
Claim 32phenotype differencesupports2014Source 1needs review

In a light-dark cycle, MPTP-treated dopamine-depleted non-human primates retain rest-wake locomotor rhythms but show reduced amplitude, decreased stability, and increased fragmentation relative to controls.

In a light∶dark cycle, control and MPTP-treated NHP both exhibit rest-wake locomotor rhythms, although DA-depleted NHP show reduced amplitude, decreased stability and increased fragmentation.
Claim 33phenotype differencesupports2014Source 1needs review

In a light-dark cycle, MPTP-treated dopamine-depleted non-human primates retain rest-wake locomotor rhythms but show reduced amplitude, decreased stability, and increased fragmentation relative to controls.

In a light∶dark cycle, control and MPTP-treated NHP both exhibit rest-wake locomotor rhythms, although DA-depleted NHP show reduced amplitude, decreased stability and increased fragmentation.
Claim 34phenotype differencesupports2014Source 1needs review

In a light-dark cycle, MPTP-treated dopamine-depleted non-human primates retain rest-wake locomotor rhythms but show reduced amplitude, decreased stability, and increased fragmentation relative to controls.

In a light∶dark cycle, control and MPTP-treated NHP both exhibit rest-wake locomotor rhythms, although DA-depleted NHP show reduced amplitude, decreased stability and increased fragmentation.
Claim 35phenotype differencesupports2014Source 1needs review

In a light-dark cycle, MPTP-treated dopamine-depleted non-human primates retain rest-wake locomotor rhythms but show reduced amplitude, decreased stability, and increased fragmentation relative to controls.

In a light∶dark cycle, control and MPTP-treated NHP both exhibit rest-wake locomotor rhythms, although DA-depleted NHP show reduced amplitude, decreased stability and increased fragmentation.

Approval Evidence

1 source1 linked approval claimfirst-pass slug in-vivo-pet-11-c-pe2i
DA degeneration was assessed by in vivo PET ([(11)C]-PE2I) and post-mortem TH and DAT quantification.

Source:

assay usagesupports

Dopamine degeneration in the MPTP non-human primate model was assessed using in vivo PET with [(11)C]-PE2I and post-mortem TH and DAT quantification.

DA degeneration was assessed by in vivo PET ([(11)C]-PE2I) and post-mortem TH and DAT quantification.

Source:

Comparisons

Source-backed strengths

The method was used in vivo and paired with post-mortem tyrosine hydroxylase and dopamine transporter quantification, supporting its role in a cross-validated assessment workflow. The supplied evidence does not report sensitivity, specificity, spatial resolution, or longitudinal performance.

in vivo PET ([(11)C]-PE2I) and fluorescence line narrowing address a similar problem space.

Shared frame: same top-level item type

in vivo PET ([(11)C]-PE2I) and Langendorff perfused heart electrical recordings address a similar problem space.

Shared frame: same top-level item type

Strengths here: looks easier to implement in practice.

in vivo PET ([(11)C]-PE2I) and native green gel system address a similar problem space.

Shared frame: same top-level item type

Strengths here: looks easier to implement in practice.

Ranked Citations

  1. 1.
    StructuralSource 1PLoS ONE2014Claim 1Claim 2Claim 3

    Seeded from load plan for claim c4. Extracted from this source document.